Pharsight

News

Mar 25, 2024
The FDA has approved Novo Nordisk’s Wegovy (semaglutide) for reducing the risk of cardiovascular death, heart attack, and stroke in people with higher BMIs, marking a new indication for the drug. Wegovy is a competitor to Eli Lilly's tirzepatide, also currently in trials for cardiovascular indications. This decision could represent a milestone in using GLP-1 agonists for conditions beyond diabetes and weight loss.
Mar 25, 2024
Amgen has filed a lawsuit against the state of Colorado over efforts by Colorado's Prescription Drug Affordability Board to possibly cap the price of the arthritis drug Enbrel. Amgen argues that the board's actions are unconstitutional and violate rights to due process. The company is seeking to overturn the board's decisions and strike down major parts of the law creating the board. Colorado lawmakers created the board in 2021 with the goal of lowering prescription costs, and it has the authority to set price caps on drugs it deems unaffordable.
Read more about | AMGEN INC |
Mar 25, 2024
Johnson & Johnson has received FDA approval for Opsynvi, a combination of the drugs Opsumit and tadalafil, for the treatment of pulmonary arterial hypertension. Opsynvi is approved for both newly diagnosed patients and those who have already been treated with Opsumit and tadalafil as separate tablets. Opsumit, owned by J&J through its acquisition of Actelion, is a blockbuster drug that generated $1.9 billion in 2023. tadalafil" style="text-decoration: underline; color: #00bdcd;">Tadalafil, the active ingredient in Cialis, was originally developed by Eli Lilly and is now available as a generic.
Mar 25, 2024
The U.S. Federal Trade Commission (FTC) has filed an amicus brief in court, accusing Teva of "improperly listing" patents for its asthma inhaler ProAir HFA in the FDA's Orange Book, blocking Amneal Pharmaceuticals' approval bid for a generic version of the inhaler. The FTC argues that these patents are "bunk" and harm competition by delaying the entry of more affordable generic drugs. The FTC is pushing for a judgment to compel the delisting of the patents in question. Teva did not respond to requests for comment.
Read more about | AMNEAL | TEVA | PROAIR HFA|
Mar 25, 2024
German pharmaceutical company Bayer AG has outlined its plan to transform its pharma business during its annual Pharma Media Day. The company will primarily focus on cardiovascular diseases, oncology, immunology, and neurology & rare diseases. Bayer aims to strengthen its pipeline through acquisitions and collaborations and has acquired the marketing rights for the cardiovascular candidate acoramidis in Europe. The company is also implementing a new operating model to reduce hierarchies and streamline structures. However, Bayer has faced setbacks with drugs like asundexian and Xarelto, and the ongoing glyphosate litigation has impacted its cash position.
Read more about | XARELTO|
Mar 25, 2024
Amgen is testing an injectable weight loss treatment called MariTide, which aims to help patients lose weight and keep it off. The drug is being designed to be taken once a month or less frequently, providing more convenience compared to weekly medicines on the market. The weight loss drug market is projected to be worth $100 billion by the end of the decade, with analysts estimating that between 10 million and 70 million Americans will be taking weight loss drugs by 2028.
Read more about | AMGEN INC |
Mar 25, 2024
AbbVie is set to acquire Landos Biopharma for up to $212 million in a bid to expand its portfolio of medicines for immune system-related illnesses. Landos is currently conducting a mid-stage study of its lead experimental drug NX-13 for the treatment of ulcerative colitis, an inflammatory bowel disease. AbbVie's acquisition of Landos will bolster its pipeline in this therapeutic area. The deal is expected to close in the second quarter.
Read more about | ABBVIE INC |
Mar 25, 2024
AbbVie, the maker of Humira, has announced plans to acquire drug developer Landos Biopharma for up to $212 million. The acquisition is part of AbbVie's strategy to expand its pipeline of medicines for immune system-related illnesses. Landos is currently conducting a mid-stage study of its lead drug NX-13, which aims to treat ulcerative colitis, an inflammatory bowel disease. The deal is expected to close in the second quarter of this year.
Read more about | ABBVIE INC |
Mar 23, 2024
Bayer showcased advancements in its pharma business at its annual Pharma Media Day 2024, highlighting progress in pipeline growth and expansion in key therapeutic areas. The company has focused on cardiovascular diseases, oncology, immunology, neurology & rare diseases, and has strengthened its innovation engine through collaborations and acquisitions. Additionally, Bayer reported positive clinical data for elinzanetant, a potential treatment for menopausal symptoms, and discussed its efforts in precision oncology, cell therapy, gene therapy, and other therapeutic areas. The company also emphasized its commitment to patient care and addressing unmet medical needs.
Mar 22, 2024
Comedian Tracy Morgan revealed that he gained 40 pounds while taking the weight loss drug Ozempic, contradicting the usual weight loss claims associated with the drug. Ozempic contains the drug semaglutide and is known to suppress hunger hormones. Experts suggest that weight gain is possible on the drug and that the body may adjust to its effects, necessitating diet and exercise choices to maintain weight loss. While studies have shown that over 86% of patients lose weight on Ozempic, individual treatment plans may be necessary for optimal results.
Read more about | OZEMPIC| SEMAGLUTIDE|